Speakers: Steven Grinspoon, M.D. (Professor of Medicine, Harvard Medical School, Chief, Metabolism Unit, MGH Endowed Chair in Neuroendocrinology and Metabolism, Director, Nutrition Obesity Research Center at Harvard)
Original Broadcast date: October 28, 2021
Over one-third of HIV patients develop nonalcoholic fatty liver disease (NAFLD) with an accelerated clinical course and high rate of fibrosis progression. Unfortunately, there are no treatment strategies currently approved to treat HIV patients with NAFLD. In this webinar, Dr. Grinspoon reviews a study in which HIV-infected patients with a hepatic fat fraction > 5% were either given a placebo or tesamorelin, a drug that reduces visceral fat, to determine whether tesamorelin could be used to treat NAFLD. After 12 months, tesamorelin significantly reduced liver fat (>30%) in 60% of treated patients compared to only 16% of patients who received the placebo. Plasma protein profiling was performed using Olink® PEA technology to understand the immunological response to tesamorelin and identify a proteomic signature of hepatic fibrosis in HIV-associated NAFLD.
The webinar covers the following points:
- Protein profiling was performed using plasma and the Olink® Explore platform
- 13 immunologic proteins differentially regulated by tesamorelin compared to placebo were identified
- Distinct protein signatures between hepatic fibrosis stages 0-1 and 2-3 were identified
If you have any questions about Olink, please contact us at info@olink.com.
